An interventional study of Difelikefalin Injection and Normal Saline (0.9% NaCl) in Itching Symptoms and CKD 5D, Hemodialysis, sponsored by Chittagong Medical College. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Chittagong Medical College · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing difelikefalin in Pruritus — 2 open to participants now, 2 under way, none of them phase 3. difelikefalin · Pruritus.
Among the 19 studies testing difelikefalin in Pruritus, this one is the 15th largest by planned enrollment, is one of 2 that started in 2026, is the only one with no phase, and was the 19th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →2 of the 19 studies testing difelikefalin in Pruritus are open now, in 7 countries. Recruiting first, the newest first:
Vifor Fresenius Medical Care Renal Pharma · Sites in China, Greece, Israel and 4 more countries
Ages 12–18
By country, each count listing its studies:
difelikefalin: first FDA approval 2021 (KORSUVA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 11
First in 2014; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 106 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 226 across the 19 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Chittagong Medical College is the lead sponsor of 15 studies on the registry; 8 are open to participants now.
Chittagong Medical College has 1 study filed under Pruritus — fewer than ten, so there is no comparison to draw.
1 of the studies testing difelikefalin in Pruritus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07526324Chittagong Medical CollegeDifelikefalin for Itching in Hemodialysis Patients With Chronic Kidney Disease | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing difelikefalin in Pruritus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, placebo-controlled, double-blind trial will be conducted in the Department of Nephrology at Chittagong Medical College Hospital, Chattogram, Bangladesh, over a period of one and a half years. A total of 102 patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis will be enrolled in the study.
Patients with moderate-to-severe pruritus, defined as a Worst Itching Intensity Numerical Rating Scale (WI-NRS) score ≥ 4, will be included. Eligible participants will be randomly assigned in a 1:1 ratio to receive either difelikefalin (0.5 mcg/kg) or placebo administered intravenously after each hemodialysis session for 6 weeks.
The primary outcome measure will be the change in WI-NRS score from baseline to week 6. Secondary outcomes will include changes in quality of life assessed using the Skindex-10 scale. Adverse events and safety parameters will also be monitored throughout the study period.
The primary analysis will be conducted using the intention-to-treat principle. A per-protocol analysis may also be performed as a secondary analysis. Statistical analysis will be carried out using SPSS version 27.
Chronic kidney disease-associated pruritus (CKD-aP), alternatively termed uremic pruritus (UP), represents a frequent, distressing, and often incapacitating clinical manifestation among individuals diagnosed with chronic kidney disease (CKD) or end-stage renal disease (ESRD). Characterized by persistent, intense itching-typically generalized but occasionally localized-CKD-aP disproportionately affects patients undergoing hemodialysis, with epidemiological studies reporting a variable prevalence ranging from 22% to 84% in this population. Notably, a substantial subset of these patients, approximately 20-40%, experience moderate-to-severe pruritus, which significantly diminishes their quality of life.
The impact of CKD-aP extends beyond physical discomfort. The condition is associated with chronic sleep disturbances such as insomnia, fatigue, and dermatological complications including excoriations, lichenification, and secondary infections due to repeated scratching. Psychosocially, patients often experience emotional distress, social withdrawal, and stigmatization related to visible skin lesions, which may worsen underlying mental health conditions such as anxiety and depression. Additionally, CKD-aP has been associated with increased mortality in dialysis patients, including higher risks of cardiovascular events and infections, suggesting a link with systemic inflammation and immune dysregulation.
There is a clear need for effective treatment options for CKD-aP. Current off-label therapies include antihistamines, topical corticosteroids, gabapentin, and pregabalin. While some of these treatments may reduce itching, their side effects can limit their use in this population.
The pathogenesis of CKD-aP remains incompletely understood. Proposed mechanisms include metabolic disturbances, immune system dysregulation, and imbalance in the endogenous opioid system, particularly involving peripheral kappa opioid receptors.
Difelikefalin is a peripherally acting, selective kappa opioid receptor agonist that exerts antipruritic effects through activation of receptors on peripheral neurons and immune cells. Its hydrophilic peptide structure limits its ability to cross the blood-brain barrier, thereby reducing central nervous system effects.
Difelikefalin has been approved as the first medication specifically indicated for CKD-aP in patients undergoing dialysis and has demonstrated efficacy in phase 3 clinical trials. It is currently recommended as a first-line treatment for moderate-to-severe CKD-aP in dialysis patients where available.
Despite promising results, some limitations remain. A proportion of patients do not achieve clinically meaningful improvement in itch intensity or quality of life. Clinical trials have demonstrated significant benefits, but response variability persists.
The safety profile of difelikefalin is dose-dependent. Common adverse effects include nausea, vomiting, dizziness, diarrhea, and gait disturbances. A dose of 0.5 μg/kg appears to provide the most favorable balance between efficacy and safety.
Although difelikefalin is a promising treatment option, current evidence remains limited, and additional well-designed randomized controlled trials are needed to confirm its effectiveness.
While most existing studies have been conducted in Western populations, data from low- and middle-income countries such as Bangladesh are limited. The prevalence of CKD in Bangladesh is high, affecting millions of individuals, with a significant number progressing to end-stage renal disease annually.
This study aims to evaluate the superiority of difelikefalin over placebo in reducing pruritus severity among patients undergoing maintenance hemodialysis in a tertiary-level teaching hospital in Bangladesh.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Difelikefalin (0.5 mcg/kg) will be administered intravenously at the end of each hemodialysis session, three times per week, for a total duration of 6 weeks in patients with CKD-associated pruritus.
Drug: Difelikefalin Injection
Participants will receive intravenous normal saline at the end of each hemodialysis session, three times per week, for 6 weeks, administered in a volume equivalent to the difelikefalin dose
Drug: Normal Saline (0.9% NaCl)
ntravenous difelikefalin (κ-opioid receptor agonist) administered at a dose of 0.5 mcg/kg at the end of each hemodialysis session, three times weekly,for a total duration of 6 wks in patients undergoing maintenance hemodialysis with moderate to severe CKD -associated pruritus
Intravenous normal saline will be administered at the end of each hemodialysis session, three times per week, for a total duration of 6 weeks, in a volume equivalent to the difelikefalin dose.
Change From Baseline in Worst Itching Intensity Numerical Rating Scale (WI-NRS) Score at 6 Weeks
The Worst Itching Intensity Numerical Rating Scale (WI-NRS) is an 11-point scale ranging from 0 (no itching) to 10 (worst imaginable itching). The outcome will be reported as the mean change in WI-NRS score from baseline to week 6
Time frame: Baseline to Week 6
Change From Baseline in Skindex-10 Score at 6 Weeks
Skindex-10 is a validated questionnaire used to assess quality of life in patients with skin conditions. Scores range from 0 to 60, with higher scores indicating worse quality of life. The outcome will be reported as the mean change from baseline to week 6.
Time frame: Baseline to Week 6
No study locations are listed for this record.
Plan to share: No — Individual participant data (IPD) will not be shared due to privacy and confidentiality concerns, as well as institutional and ethical restrictions
Start is estimated for Apr 2026; primary completion for Jan 2027, 9 months later.
Of 85 non-industry interventional studies with no phase under Pruritus, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 9 months is above that.
Counting every sponsor, half of 101 studies reached it within 7 months; a quarter within 3 and three quarters within 13.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difelikefalin
Chittagong Medical College